The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

A large database analysis finds that survival differences between men and women with metastatic melanoma disappear when ...

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...

RMAT designation requires preliminary clinical evidence addressing an unmet need in a serious disease and provides Fast Track ...

In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of ...

Long-term clinical trials show patients with stage four kidney cancer are living a decade or more beyond previous expectations.

Dozens of drugs can alter the immune system and affect activity of immune checkpoint inhib ...

Investigators analyzed economic evaluations of adjuvant immunotherapy to assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches.

A combination immunotherapy approach using Ampligen (rintatolimod) and Imfinzi (durvalumab) showed clinical activity for ...